RedHill Biopharma Ltd. (RDHL)
| Market Cap | 221.92M |
| Revenue (ttm) | 84.48M |
| Net Income (ttm) | -94.95M |
| Shares Out | 46.72M |
| EPS (ttm) | -2.31 |
| PE Ratio | n/a |
| Forward PE | 1,428.57 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 739,575 |
| Open | 4.73 |
| Previous Close | 4.75 |
| Day's Range | 4.71 - 4.98 |
| 52-Week Range | 4.48 - 11.52 |
| Beta | 1.40 |
| Analysts | Strong Buy |
| Price Target | 18.79 (+280.3%) |
| Est. Earnings Date | Nov 11, 2021 |
About RDHL
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infectio...
Financial Performance
In 2020, RDHL's revenue was $64.36 million, an increase of 923.03% compared to the previous year's $6.29 million. Losses were -$76.17 million, 80.1% more than in 2019.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for RDHL stock is "Strong Buy." The 12-month stock price forecast is 18.79, which is an increase of 280.28% from the latest price.
News
RedHill Settles Movantik Patent Litigation With Aurobindo
RedHill Biopharma Ltd (NASDAQ: RDHL) has announced a settlement and license agreement with Aurobindo Pharma USA Inc resolving their patent litigation in the U.S. The litigation was related to Aurobindo'...
RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with Aurobindo
TEL AVIV, Israel and RALEIGH, N.C., Sept. 23, 2021 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill (RDHL) Down on Unsatisfactory Data From COVID-19 Study
RedHill (RDHL) posts preliminary top-line data from a phase II/III study evaluating opaganib in hospitalized patients with severe COVID-19 pneumonia. Stocks falls as the study fails to achieve its goal.
Why RedHill Biopharma Stock Is Getting Crushed Today
A clinical failure is sending shareholders to the exits this morning.
What's Happening With RedHill Biopharma's Stock On Tuesday?
RedHill Biopharma Ltd (NASDAQ: RDHL) announced preliminary top-line data from Phase 2/3 study evaluating opaganib in hospitalized patients with severe COVID-19 pneumonia. Read Next: RedHill Biopharma ...
RedHill Biopharma Reports Top-Line Data from Opaganib Phase 2/3 Study in Severe COVID-19 Patients
TEL AVIV, Israel and RALEIGH, NC, Sept. 14, 2021 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill Biopharma To Test Its Oral Antiviral In COVID-19 Patients In South Africa
Regulatory authorities in South Africa have signed off RedHill Biopharma Ltd's (NASDAQ: RDHL) Phase 2/3 study evaluating RHB-107 (upamostat) for non-hospitalized patients with symptomatic COVID-19. The...
RHB-107 P2/3 COVID-19 Study South Africa Approval
RedHill Biopharma Accelerates Ongoing U.S. Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients with South African Approval The South African Health Products Regulatory Autho...
RedHill Biopharma Accelerates Ongoing U.S. Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Pa...
The South African Health Products Regulatory Authority (SAHPRA) has approved the Phase 2/3 study of once-daily orally-administered RHB-107 (upamostat) for patients with symptomatic COVID-19 who do not r...
RedHill's (RDHL) Opaganib Effective Against Kidney Fibrosis
Opaganib, Redhill's (RDHL) candidate for COVID-19, achieves a significant reduction in kidney fibrosis in preclinical studies.
RedHill Unveils New Movantik Data For Opioid-Induced Constipation
RedHill Biopharma Ltd (NASDAQ: RDHL) has announced new Movantik (naloxegol) Phase 3 study data analyses. The three analyses included pooled data from two Phase 3 studies involving 891 treated patients a...
RedHill Biopharma's Opaganib Demonstrates Significant Decrease of Kidney Fibrosis
COVID-19 and long COVID patients are at increased risk of developing kidney damage - Opaganib significantly decreased kidney fibrosis in a preclinical in vivo model - Renal fibrosis is a progressive pro...
RedHill Biopharma Ltd Announces New Movantik Analyses at PAINWeek
RedHill Biopharma Presents Three New Analyses of Movantik Data at PAINWeek 2021 Two new analyses of Movantik® (naloxegol) data evaluated the safety and efficacy of Movantik in a subgroup of patients age...
RedHill Biopharma Presents Three New Analyses of Movantik Data at PAINWeek 2021
TEL AVIV, Israel and RALEIGH, N.C., Sept. 7, 2021 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill to Present at HCW & Cantor Conferences
RedHill Biopharma to Present at H.C. Wainwright Annual Global Investment and Cantor Global Healthcare Conferences TEL AVIV, ISRAEL and RALEIGH, NC / ACCESSWIRE / September 2, 2021 / RedHill Biopharma Ltd.
RedHill Biopharma to Present at H.C. Wainwright Annual Global Investment and Cantor Global Healthcare Conferences
TEL AVIV, Israel and RALEIGH, NC, Sept. 2, 2021 /PRNewswire/ -- RedHill Biopharma Ltd.
Why RedHill Biopharma Stock Jumped on Tuesday
An analyst on Wall Street thinks the company's commercial and development pipeline has been underestimated.
Cantor Sees 'Compelling Investment Opportunity' In This Biopharma
Cantor Fitzgerald has initiated coverage of RedHill Biopharma Ltd (NASDAQ:RDHL) with an Overweight rating and a $22 price target, an upside of approximately 115%. Redhill is focused on the development a...
RedHill Biopharma's Oral COVID-19 Candidate Shows Preclinical Action Against Delta Variant
RedHill Biopharma Ltd (NASDAQ: RDHL) has announced preliminary results of a new preclinical study for its COVID-19 treatment candidate, opaganib. Related: RedHill's Novel Late-Stage Pills Hold Promise...
Redhill Biopharma: Q2 Earnings Insights
Shares of Redhill Biopharma (NASDAQ:RDHL) rose 11.1% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 250.00% year over year to ($0.06), which ...
RedHill Reports Second Quarter 2021 Results
Achieved record quarterly revenues of $21.5 million for Q2/2021, 4.5% increase from Q1/2021 despite challenging market conditions; Cash balance[1] of approximately $71.5 million as of June 30, 2021 Reco...
RedHill Biopharma Reports Second Quarter 2021 Financial Results and Operational Highlights
TEL AVIV, Israel and RALEIGH, N.C., Aug. 26, 2021 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill Biopharma Ltd Announces RedHill's Opaganib Strong Delta Variant Inhibition
RedHill Biopharma's Opaganib Demonstrates Strong Inhibition of COVID-19 Delta Variant Opaganib demonstrated strong inhibition of COVID-19 Delta variant in a human bronchial epithelial cells model, addin...
RedHill Biopharma's Opaganib Demonstrates Strong Inhibition of COVID-19 Delta Variant
TEL AVIV, Israel and RALEIGH, N.C., Aug. 26, 2021 /PRNewswire/ -- RedHill Biopharma Ltd.
A Preview Of Redhill Biopharma's Earnings
Redhill Biopharma (NASDAQ:RDHL) will be releasing its next round of earnings this Thursday, August 26. For all of the relevant information, here is your guide for Thursday's Q2 earnings announcement.